Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

Explaining disparities in oncology health systems delays and stage at diagnosis between men and women in Botswana: A cohort study.

Iyer HS, Kohler RE, Ramogola-Masire D, Brown C, Molebatsi K, Grover S, Kablay I, Bvochora-Nsingo M, Efstathiou JA, Lockman S, Tapela N, Dryden-Peterson SL.

PLoS One. 2019 Jun 6;14(6):e0218094. doi: 10.1371/journal.pone.0218094. eCollection 2019.

2.

The current state of randomized clinical trial evidence for prostate brachytherapy.

Dess RT, Soni PD, Jackson WC, Berlin A, Cox BW, Jolly S, Efstathiou JA, Feng FY, Kishan AU, Stish BJ, Pisansky TM, Spratt DE.

Urol Oncol. 2019 May 3. pii: S1078-1439(19)30142-5. doi: 10.1016/j.urolonc.2019.04.009. [Epub ahead of print] Review.

PMID:
31060795
3.

Proton versus photon-based radiation therapy for prostate cancer: emerging evidence and considerations in the era of value-based cancer care.

Kamran SC, Light JO, Efstathiou JA.

Prostate Cancer Prostatic Dis. 2019 Apr 9. doi: 10.1038/s41391-019-0140-7. [Epub ahead of print] Review.

PMID:
30967625
4.

Molecular Characterization of Neuroendocrine-like Bladder Cancer.

Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, Lotan Y, Black PC.

Clin Cancer Res. 2019 Apr 5. doi: 10.1158/1078-0432.CCR-18-3558. [Epub ahead of print]

PMID:
30952638
5.

Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies.

Solanki AA, Bossi A, Efstathiou JA, Lock D, Mondini M, Ramapriyan R, Welsh J, Kang J.

Eur Urol Oncol. 2019 Feb;2(1):79-87. doi: 10.1016/j.euo.2018.09.013. Epub 2018 Nov 16. Review.

PMID:
30929848
7.

Editorial comment.

Royce TJ, Efstathiou JA.

Urology. 2019 Feb;124:189-190. doi: 10.1016/j.urology.2018.07.060. No abstract available.

PMID:
30784711
8.

Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.

Efstathiou JA, Mouw KW, Gibb EA, Liu Y, Wu CL, Drumm MR, da Costa JB, du Plessis M, Wang NQ, Davicioni E, Feng FY, Seiler R, Black PC, Shipley WU, Miyamoto DT.

Eur Urol. 2019 Feb 1. pii: S0302-2838(19)30012-0. doi: 10.1016/j.eururo.2019.01.011. [Epub ahead of print]

PMID:
30712971
9.

SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.

Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ, Sankin AI, Schoenberg MP, Shipley WU, Villers A, Efstathiou JA, Bellmunt J, Stenzl A.

World J Urol. 2019 Jan;37(1):61-83. doi: 10.1007/s00345-018-2606-y. Epub 2019 Jan 25. Review.

PMID:
30684034
10.

Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years.

Salari K, Kuppermann D, Preston MA, Dahl DM, Barrisford GW, Efstathiou JA, Blute ML, Vesprini D, Loblaw A, Zietman AL, Klotz L, Feldman AS.

J Urol. 2019 Apr;201(4):721-727. doi: 10.1097/JU.0000000000000031.

PMID:
30664083
11.

Safeguarding Autonomy of Patients With Bladder Cancer.

Yerramilli D, Moghanaki DM, Efstathiou JA.

Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):81-83. doi: 10.1016/j.ijrobp.2018.07.2019. Epub 2018 Dec 12. No abstract available.

PMID:
30563669
12.

Proton therapy for prostate cancer: A review of the rationale, evidence, and current state.

Royce TJ, Efstathiou JA.

Urol Oncol. 2018 Dec 4. pii: S1078-1439(18)30460-5. doi: 10.1016/j.urolonc.2018.11.012. [Epub ahead of print] Review.

PMID:
30527342
13.

Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer.

Miyamoto DT, Mouw KW, Feng FY, Shipley WU, Efstathiou JA.

Lancet Oncol. 2018 Dec;19(12):e683-e695. doi: 10.1016/S1470-2045(18)30693-4. Review.

PMID:
30507435
14.

Long-term impact of a faculty mentoring program in academic medicine.

Efstathiou JA, Drumm MR, Paly JP, Lawton DM, O'Neill RM, Niemierko A, Leffert LR, Loeffler JS, Shih HA.

PLoS One. 2018 Nov 29;13(11):e0207634. doi: 10.1371/journal.pone.0207634. eCollection 2018.

15.

Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.

Royce TJ, Feldman AS, Mossanen M, Yang JC, Shipley WU, Pandharipande PV, Efstathiou JA.

Clin Genitourin Cancer. 2019 Feb;17(1):23-31.e3. doi: 10.1016/j.clgc.2018.09.023. Epub 2018 Oct 4.

PMID:
30482661
16.

Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer.

Efstathiou JA, Choudhury A, Kiltie AE.

JAMA Surg. 2018 Nov 21. doi: 10.1001/jamasurg.2018.4370. [Epub ahead of print] No abstract available.

PMID:
30477011
17.

Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.

Coen JJ, Zhang P, Saylor PJ, Lee CT, Wu CL, Parker W, Lautenschlaeger T, Zietman AL, Efstathiou JA, Jani AB, Kucuk O, Souhami L, Rodgers JP, Sandler HM, Shipley WU.

J Clin Oncol. 2019 Jan 1;37(1):44-51. doi: 10.1200/JCO.18.00537. Epub 2018 Nov 15.

18.

Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy-Reply.

Hwang WL, Niemierko A, Efstathiou JA.

JAMA Oncol. 2018 Nov 1;4(11):1620-1621. doi: 10.1001/jamaoncol.2018.3552. No abstract available.

PMID:
30422248
19.

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA.

J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053. doi: 10.6004/jnccn.2018.0072.

PMID:
30181416
20.

Impact of interfractional motion on hypofractionated pencil beam scanning proton therapy and VMAT delivery for prostate cancer.

Moteabbed M, Trofimov A, Khan FH, Wang Y, Sharp GC, Zietman AL, Efstathiou JA, Lu HM.

Med Phys. 2018 Jul 14. doi: 10.1002/mp.13091. [Epub ahead of print]

PMID:
30007067
21.

Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer.

Lukka HR, Pugh SL, Bruner DW, Bahary JP, Lawton CAF, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M 3rd, Pinover WH, Beyer DC, Amanie JO, Sandler HM, Kachnic LA.

Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):287-295. doi: 10.1016/j.ijrobp.2018.06.008. Epub 2018 Jun 18.

PMID:
29913254
22.

Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer.

Bryant AK, Kader AK, McKay RR, Einck JP, Mell LK, Mundt AJ, Kane CJ, Efstathiou JA, Murphy JD, Rose BS.

Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1188-1193. doi: 10.1016/j.ijrobp.2018.04.023. Epub 2018 Apr 17.

PMID:
29891203
23.

Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System).

Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, Huddart R, Kennish S, Lerner S, Montironi R, Muglia VF, Salomon G, Thomas S, Vargas HA, Witjes JA, Takeuchi M, Barentsz J, Catto JWF.

Eur Urol. 2018 Sep;74(3):294-306. doi: 10.1016/j.eururo.2018.04.029. Epub 2018 May 10. Review.

PMID:
29755006
24.

PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.

Liu Q, Gheorghiu L, Drumm M, Clayman R, Eidelman A, Wszolek MF, Olumi A, Feldman A, Wang M, Marcar L, Citrin DE, Wu CL, Benes CH, Efstathiou JA, Willers H.

Oncogene. 2018 May;37(21):2793-2805. doi: 10.1038/s41388-018-0130-6. Epub 2018 Mar 7.

25.

Clinical needs assessment for sexual health among cancer patients receiving pelvic radiation: Implications for development of a radiation oncology sexual health clinic.

Wo JY, Drapek LC, Niemierko A, Silvia B, Noé BN, Russo AL, Miyamoto DT, Hong TS, Efstathiou JA, Zietman AL, Dizon DS.

Pract Radiat Oncol. 2018 May - Jun;8(3):206-212. doi: 10.1016/j.prro.2017.11.004. Epub 2017 Nov 21.

PMID:
29426693
26.

Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features.

Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, Spratt DE, Hearn JW, Koontz BF, Lee WR, Michalski JM, Pisansky TM, Liauw SL, Abramowitz MC, Pollack A, Moghanaki D, Anscher MS, Den RB, Zietman AL, Stephenson AJ, Efstathiou JA.

JAMA Oncol. 2018 May 10;4(5):e175230. doi: 10.1001/jamaoncol.2017.5230. Epub 2018 May 10.

27.

An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer.

Miyamoto DT, Lee RJ, Kalinich M, LiCausi JA, Zheng Y, Chen T, Milner JD, Emmons E, Ho U, Broderick K, Silva E, Javaid S, Kwan TT, Hong X, Dahl DM, McGovern FJ, Efstathiou JA, Smith MR, Sequist LV, Kapur R, Wu CL, Stott SL, Ting DT, Giobbie-Hurder A, Toner M, Maheswaran S, Haber DA.

Cancer Discov. 2018 Mar;8(3):288-303. doi: 10.1158/2159-8290.CD-16-1406. Epub 2018 Jan 4.

28.

Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer.

Harshman LC, Tripathi A, Kaag M, Efstathiou JA, Apolo AB, Hoffman-Censits JH, Stadler WM, Yu EY, Bochner BH, Skinner EC, Downs T, Kiltie AE, Bajorin DF, Guru K, Shipley WU, Steinberg GD, Hahn NM, Sridhar SS.

Clin Genitourin Cancer. 2018 Jun;16(3):213-218. doi: 10.1016/j.clgc.2017.11.004. Epub 2017 Dec 6.

PMID:
29289519
29.

Clinical characteristics and outcomes of nonurothelial cell carcinoma of the bladder: Results from the National Cancer Data Base.

Royce TJ, Lin CC, Gray PJ, Shipley WU, Jemal A, Efstathiou JA.

Urol Oncol. 2018 Feb;36(2):78.e1-78.e12. doi: 10.1016/j.urolonc.2017.10.013. Epub 2017 Nov 20.

PMID:
29162314
30.

Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.

Ramey SJ, Agrawal S, Abramowitz MC, Moghanaki D, Pisansky TM, Efstathiou JA, Michalski JM, Spratt DE, Hearn JWD, Koontz BF, Liauw SL, Pollack A, Anscher MS, Den RB, Stephans KL, Zietman AL, Lee WR, Stephenson AJ, Tendulkar RD.

Eur Urol. 2018 Jul;74(1):99-106. doi: 10.1016/j.eururo.2017.10.009. Epub 2017 Nov 9.

PMID:
29128208
31.

Multicriteria plan optimization in the hands of physicians: a pilot study in prostate cancer and brain tumors.

Müller BS, Shih HA, Efstathiou JA, Bortfeld T, Craft D.

Radiat Oncol. 2017 Nov 6;12(1):168. doi: 10.1186/s13014-017-0903-z.

32.

The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinoma.

Gakis G, Schubert T, Morgan TM, Daneshmand S, Keegan KA, Mischinger J, Clayman RH, Brisuda A, Ali-El-Dein B, Galland S, Gregg J, Balci M, Olugbade K Jr, Rink M, Fritsche HM, Burger M, Babjuk M, Stenzl A, Thalmann GN, Kübler H, Efstathiou JA.

Urol Oncol. 2018 Jan;36(1):10.e7-10.e14. doi: 10.1016/j.urolonc.2017.09.012. Epub 2017 Oct 18.

PMID:
29055518
33.

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA.

J Natl Compr Canc Netw. 2017 Oct;15(10):1240-1267. doi: 10.6004/jnccn.2017.0156.

PMID:
28982750
34.

Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer.

Sanchez A, Wszolek MF, Niemierko A, Clayman RH, Drumm M, Rodríguez D, Feldman AS, Dahl DM, Heney NM, Shipley WU, Zietman AL, Efstathiou JA.

J Urol. 2018 Feb;199(2):407-415. doi: 10.1016/j.juro.2017.08.106. Epub 2017 Sep 1.

PMID:
28870862
35.

Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-term Results of a Single-institution Experience.

Rodin D, Drumm M, Clayman R, Buscariollo DL, Galland-Girodet S, Eidelman A, Feldman AS, Dahl DM, McGovern FJ, Olumi AF, Niemierko A, Shipley WU, Zietman AL, Efstathiou JA.

Clin Genitourin Cancer. 2017 Aug 3. pii: S1558-7673(17)30236-7. doi: 10.1016/j.clgc.2017.07.026. [Epub ahead of print]

PMID:
28864223
36.

Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience.

Kamran SC, Harshman LC, Bhagwat MS, Muralidhar V, Nguyen PL, Martin NE, La Follette S, Faso S, Viswanathan AN, Efstathiou JA, Beard CJ.

Adv Radiat Oncol. 2017 Jan 17;2(2):140-147. doi: 10.1016/j.adro.2017.01.001. eCollection 2017 Apr-Jun.

37.

The Natural History and Outcome Predictors of Metastatic Castration-resistant Prostate Cancer.

van Soest RJ, Efstathiou JA, Sternberg CN, Tombal B.

Eur Urol Focus. 2016 Dec;2(5):480-487. doi: 10.1016/j.euf.2016.12.006. Epub 2017 Jan 6. Review.

PMID:
28723513
39.

Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade.

Jang JW, Drumm MR, Efstathiou JA, Paly JJ, Niemierko A, Ancukiewicz M, Talcott JA, Clark JA, Zietman AL.

Cancer Med. 2017 Jul;6(7):1827-1836. doi: 10.1002/cam4.1103. Epub 2017 May 31.

40.

Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer.

Muralidhar V, Mahal BA, Rose BS, Chen YW, Nezolosky MD, Efstathiou JA, Beard CJ, Martin NE, Orio PF 3rd, Trinh QD, Choueiri TK, Sweeney CJ, Nguyen PL.

Clin Genitourin Cancer. 2017 Oct;15(5):563-569.e3. doi: 10.1016/j.clgc.2016.10.011. Epub 2016 Oct 28.

PMID:
28462857
41.

Dosimetric impacts of endorectal balloon in CyberKnife stereotactic body radiation therapy (SBRT) for early-stage prostate cancer.

Xiang HF, Lu HM, Efstathiou JA, Zietman AL, De Armas R, Harris K, Bloch BN, Qureshi MM, Keohan S, Hirsch AE.

J Appl Clin Med Phys. 2017 May;18(3):37-43. doi: 10.1002/acm2.12063. Epub 2017 Apr 13.

42.

Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience.

Buscariollo DL, Drumm M, Niemierko A, Clayman RH, Galland-Girodet S, Rodin D, Feldman AS, M Dahl D, McGovern FJ, F Olumi A, Eidelman A, Shipley WU, Zietman AL, Efstathiou JA.

Pract Radiat Oncol. 2017 Mar - Apr;7(2):e125-e133. doi: 10.1016/j.prro.2016.10.010. Epub 2016 Oct 19.

PMID:
28274403
43.

Proton therapy of prostate cancer by anterior-oblique beams: implications of setup and anatomy variations.

Moteabbed M, Trofimov A, Sharp GC, Wang Y, Zietman AL, Efstathiou JA, Lu HM.

Phys Med Biol. 2017 Mar 7;62(5):1644-1660. doi: 10.1088/1361-6560/62/5/1644. Epub 2017 Feb 6.

PMID:
28166057
44.

The Rationale for Post-Operative Radiation in Localized Bladder Cancer.

Baumann BC, Sargos P, Eapen LJ, Efstathiou JA, Choudhury A, Bahl A, Murthy V, Ballas LK, Fonteyne V, Richaud PM, Zaghloul MS, Christodouleas JP.

Bladder Cancer. 2017 Jan 27;3(1):19-30. doi: 10.3233/BLC-160081. Review.

45.

Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.

Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, Michaelson MD, Lee RJ, Saylor PJ, Wszolek MF, Feldman AS, Dahl DM, Zietman AL, Efstathiou JA.

Eur Urol. 2017 Jun;71(6):952-960. doi: 10.1016/j.eururo.2016.12.020. Epub 2017 Jan 9.

PMID:
28081860
46.

Hydrogel rectum-prostate spacers mitigate the uncertainties in proton relative biological effectiveness associated with anterior-oblique beams.

Underwood TS, Voog JC, Moteabbed M, Tang S, Soffen E, Cahlon O, Lu HM, Zietman AL, Efstathiou JA, Paganetti H.

Acta Oncol. 2017 Apr;56(4):575-581. doi: 10.1080/0284186X.2016.1275781. Epub 2017 Jan 11.

PMID:
28075206
47.

Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy.

Krasnow RE, Drumm M, Roberts HJ, Niemierko A, Wu CL, Wu S, Zhang J, Heney NM, Wszolek MF, Blute ML, Feldman AS, Lee RJ, Zietman AL, Shipley WU, Efstathiou JA.

Eur Urol. 2017 Jul;72(1):54-60. doi: 10.1016/j.eururo.2016.12.002. Epub 2016 Dec 28.

PMID:
28040351
48.

Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop.

Smith GL, Ganz PA, Bekelman JE, Chmura SJ, Dignam JJ, Efstathiou JA, Jagsi R, Johnstone PA, Steinberg ML, Williams SB, Yu JB, Zietman AL, Weichselbaum RR, Tina Shih YC.

Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):450-461. doi: 10.1016/j.ijrobp.2016.10.042. Epub 2016 Nov 8.

49.

Introduction.

Efstathiou JA.

Semin Radiat Oncol. 2017 Jan;27(1):1-2. doi: 10.1016/j.semradonc.2016.10.001. Epub 2016 Oct 5. No abstract available.

PMID:
27986206
50.

Painting Dose: The ART of Radiation.

Roberts HJ, Zietman AL, Efstathiou JA.

Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):722-728. doi: 10.1016/j.ijrobp.2016.08.010. Epub 2016 Aug 20. Review.

PMID:
27788945

Supplemental Content

Loading ...
Support Center